Premium
Evaluation of CA 125 as a serum marker of hepatocellular carcinoma
Author(s) -
Elias John,
Kew Michael C.
Publication year - 1990
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910460510
Subject(s) - hepatocellular carcinoma , medicine , cirrhosis , gastroenterology , viral hepatitis , carcinoma , chronic liver disease , pathology , tumor marker , parenchyma , hepatitis , cancer
Abstract Serum CA 125 concentrations were raised in 90.4% of 115 southern African black patients with hepatocellular carcinoma. Seventy‐four percent of 62 patients with amebic hepatic abscess, 60% of 40 patients with chronic hepatic parenchymal disease (chronic hepatitis or cirrhosis), and 60.9% of 41 patients with acute viral hepatitis also had raised values. The median serum CA 125 concentration for patients with hepatocellular carcinoma differed significantly from the benign hepatic disease groups analysed ( p < 0.0002). Serum alphafetoprotein levels were raised in 90.4% of the 115 hepatocellular carcinoma patients. CA 125 is thus a highly sensitive marker for hepatocellular carcinoma, but lacks specificity.